FDA Grants Accelerated Approval to Mosunetuzumab-axgb for R/R Follicular Lymphoma

On December 22, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mosunetuzumab-axgb for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.

For more information, read Genetech's new release.

Posted 12/23/2022